{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:02Z","timestamp":1791855782504,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T00:00:00Z","timestamp":1369267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T00:00:00Z","timestamp":1369267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00467-013-2485-9","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T06:22:10Z","timestamp":1369203730000},"page":"1875-1879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome"],"prefix":"10.1007","volume":"28","author":[{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dorfm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Desch\u00eanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,23]]},"reference":[{"key":"2485_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269\u20131279","journal-title":"Pediatr Nephrol"},{"key":"2485_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321\u20131328","journal-title":"Pediatr Nephrol"},{"key":"2485_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, Baudouin V, Desch\u00eanes G (2010) Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 25:1109\u20131115","journal-title":"Pediatr Nephrol"},{"key":"2485_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207\u20132212","journal-title":"Clin J Am Soc Nephrol"},{"key":"2485_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytula","year":"2010","unstructured":"Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25:461\u2013468","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2485_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Gu\u00e9rin V, Lapillonne H, Desch\u00eanes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery. Nephrol Dial Transplant 27(3):1083\u20131089","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2485_CR7","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, D\u00f6tsch J (2012) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27(5):1910\u20131915","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2485_CR8","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896\u20133908","journal-title":"Arthritis Rheum"},{"key":"2485_CR9","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753\u20131755","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2485_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00467-009-1408-2","volume":"5","author":"K Kamei","year":"2010","unstructured":"Kamei K, Ito S, Iijima K (2010) Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 5(6):1193","journal-title":"Pediatr Nephrol"},{"key":"2485_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"2485_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145\u2013149","journal-title":"Pediatr Nephrol"},{"key":"2485_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00246-012-0350-4","volume":"33","author":"GC Bhatt","year":"2012","unstructured":"Bhatt GC, Sankar J, Kushwaha KP (2012) Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol 33:1370\u20131376","journal-title":"Pediatr Cardiol"},{"key":"2485_CR14","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM (2010) Severe ulcerative colitis after rituximab therapy. Pediatrics 126:e243\u2013246","journal-title":"Pediatrics"},{"key":"2485_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12016-007-8020-7","volume":"34","author":"L Sailler","year":"2008","unstructured":"Sailler L (2008) Rituximab off label use for difficult-to-treat auto-immune diseases: Reappraisal of benefits and risks. Clinic Rev Allerg Immunol 34:103\u2013110","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2485_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/ard.2007.081166","volume":"67","author":"H Marotte","year":"2008","unstructured":"Marotte H, Paintaud G, Watier H, Miossec P (2008) Rituximab related late-onset neutropenia in a patient with severe rheumatoid athritis. Ann Rheum Dis 67:893\u2013894","journal-title":"Ann Rheum Dis"},{"key":"2485_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149:3\u201313","journal-title":"Br J Haematol"},{"issue":"5","key":"2485_CR18","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, Schlesier M, Voll RE, Thiel J (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 7(5):e37626","journal-title":"PLoS One"},{"issue":"5","key":"2485_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De La Torre","year":"2012","unstructured":"De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 51(5):833\u2013840","journal-title":"Rheumatology (Oxford)"},{"key":"2485_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-0609.2005.00552.x","volume":"75","author":"M Nishio","year":"2005","unstructured":"Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, Kumano K, Minauchi K, Koike T (2005) Persistent pan-hypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 75:527\u2013529","journal-title":"Eur J Haematol"},{"key":"2485_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/07357900701809068","volume":"26","author":"AR Walker","year":"2008","unstructured":"Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW (2008) Profound hypogammaglobulinemia 7\u00a0years after treatment for indolent lymphoma. Cancer Invest 26:431\u2013433","journal-title":"Cancer Invest"},{"key":"2485_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456\u2013473","journal-title":"Cancer Treat Rev"},{"key":"2485_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54:723\u2013732","journal-title":"Arthritis Rheum"},{"key":"2485_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146:120\u2013122","journal-title":"Br J Haematol"},{"key":"2485_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2353-5","author":"E Besada","year":"2011","unstructured":"Besada E, Bader L, Nossent H (2011) Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases. Rheumatol Int. doi:10.1007\/s00296-011-2353-5","journal-title":"Rheumatol Int"},{"issue":"5","key":"2485_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.amjoto.2012.01.006","volume":"33","author":"MD Otremba","year":"2012","unstructured":"Otremba MD, Adam SI, Price CC, Hohuan D, Kveton JF (2012) Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia. Am J Otolaryngol 33(5):619\u2013622","journal-title":"Am J Otolaryngol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-013-2485-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2485-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:29:51Z","timestamp":1744172991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-013-2485-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,23]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2485"],"URL":"https:\/\/doi.org\/10.1007\/s00467-013-2485-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,23]]},"assertion":[{"value":"14 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}